Zymeworks Inc. (ZYME)

Shares of Zymeworks Inc. (NYSE: ZYME - Get Free Report) have earned an average recommendation of "Buy" from the ten brokerages that are covering the stock, Marketbeat reports. Ten investment analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have updated their coverage on the stock in the

Zymeworks Inc. (ZYME) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera ® across HER2-driven gastrointestinal cancers by partner Jazz • Zymeworks to present a Trial-in-Progress poster for ZW251, a GPC3-targeting antibody-drug conjugate for hepatocellular carcinoma at ASCO GI • Management will present at J.P. Morgan Healthcare Conference on January 14 at 3:00 pm Pacific Time (PT) VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced participation in the following upcoming conferences.

Acerus Pharmaceuticals (OTCMKTS:ASPCF - Get Free Report) and Zymeworks (NASDAQ: ZYME - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends. Valuation and Earnings This table compares Acerus Pharmaceuticals

VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences: Evercore 8th Annual Healthcare Conference in Miami: Zymeworks' management will participate in one-on-one meetings and a fireside chat on December 2, 2025, at 10:00 am Eastern Time (ET) in Miami, FL. Citi 2025 Global Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on December 3, 2025 at 3:15 pm ET in Miami, FL.

Zymeworks is gaining momentum as Ziihera shows strong Phase III data in HER2+ gastroesophageal adenocarcinoma, supporting growth and de-risking the investment. ZYME's royalty-based business model with partners like Jazz and BeOne enables pipeline focus while targeting blockbuster potential, with peak sales estimates exceeding $2B for Ziihera. Risks remain, including regulatory uncertainties and competition from ENHERTU, but ZYME's solid cash position and clinical progress support a 3/5 conviction rating.

This article revisits Zymeworks Inc. following significant new trial data released this week. This triggered a 30% rally in ZYME stock on Monday, even as most of any future revenues will accrue to partners Jazz Pharmaceuticals and BeOne. Zymeworks does have a solid balance sheet, several additional partnerships with major drug concerns, and multiple other ADCs in development.

Zymeworks Inc. ( ZYME ) Shareholder/Analyst Call November 18, 2025 8:30 AM EST Company Participants Shrinal Inamdar - Director of Investor Relations Kenneth Galbraith - Chairman of the Board, CEO & President Conference Call Participants Seung Won Paik - LifeSci Capital, LLC, Research Division Andrew Berens - Leerink Partners LLC, Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Joohwan Kim Jonathan Miller - Evercore ISI Institutional Equities, Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Yaron Werber - TD Cowen, Research Division Eva Fortea-Verdejo - Wells Fargo Securities, LLC, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Presentation Operator Thank you for standing by, and welcome to Zymeworks Strategy Update Conference Call and Webcast.

VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott Platshon as Acting Chief Investment Officer.

VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced a novel strategic initiative focused on optimizing future cash flows from Ziihera® (zanidatamab-hrii), other licensed products and other healthcare assets. Together with the ability to leverage existing and future R&D partnerships and collaborations through internal innovation, this strategy seeks to optimize a long-term source of growing revenue streams with carefully managed R&D investments to establish a durable, profitable operating structure.

Jazz Pharmaceuticals plc and Zymeworks Inc. announced positive topline phase 3 results for Ziihera in HER2-positive gastroesophageal adenocarcinoma. Ziihera in combination with chemotherapy and in combination with Tevimbra and chemotherapy outperformed trastuzumab plus chemotherapy, and the triple combination achieved statistically significant overall survival benefit. The GEA indication represents a $2 billion+ a year opportunity for JAZZ and a $300 million opportunity for BeOne, and ZYME stands to benefit by receiving royalties from both partners.

Zymeworks Inc. (ZYME) surged after positive Phase 3 results for Ziihera in first-line HER2-positive gastroesophageal adenocarcinoma, expanding its FDA-approved indications. ZYME's partnership-driven model, strong cash position, and milestone revenues limit capital risk and provide a projected runway into 2H27. The positive Ziihera data supports regulatory submission in 2026, with key catalysts including full data presentation and sBLA filing, and potential label expansion.

Zymeworks Inc. (NASDAQ: ZYME) stock is surging on Monday, with a session volume of 2.17 million, compared to an average volume of 728.75K, according to Benzinga Pro.

The companies' drug Ziihera shows clinically meaningful benefits for patients with gastroesophageal adenocarcinoma.

VANCOUVER, British Columbia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced positive topline results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab-hrii) in combination with chemotherapy, with or without the PD-1 inhibitor Tevimbra® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma, including cancers of the stomach, gastroesophageal junction, and esophagus. The results were announced today by Zymeworks' development and commercialization partners, Jazz Pharmaceuticals (Jazz) and BeOne Medicines (BeOne).

Zymeworks (NYSE: ZYME - Get Free Report) and Comera Life Sciences (NASDAQ: CMRA - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability. Volatility and Risk Zymeworks has a beta